12 Most Oversold Healthcare Stocks to Buy Now

Page 4 of 12

9. Elanco Animal Health Incorporated (NYSE:ELAN)

Year Perf: -30.26%

Analyst Upside: 60.64%

Number of Hedge Fund Holders: 42

Elanco Animal Health Incorporated (NYSE:ELAN) is an animal health company that delivers services and products that prevent and treat disease in pets and farm animals. Its diverse portfolio serves animals across various species, primarily cats, dogs, cattle, swine, poultry, and sheep.

The company’s product offerings are divided into Farm Animal and Pet Health. The Pet Health portfolio specializes in parasiticides, therapeutics, and vaccines. It also offers products that grant protection from ticks, fleas, and internal parasites. The Farm Animal portfolio focuses on swine, cattle, and poultry and includes an elaborate list of products. These include Denagard, Baycox, Experior, Rumensin, Monteban, Baycox, Maxiban, Comforta, Catosal, and others.

The company is strategically focused on streamlining its operations while progressing in its innovative product pipelines, demonstrating significant growth opportunities. The launch of Credelio Quattro, which is expected in Q1 2025, is expected to support the company’s position in the parasiticide segment. Furthermore, the strong performance of Experior, primarily in the heifer market, is anticipated to significantly contribute to its growth in 2025.

The potential success of such products, together with the ongoing expansion of Zenrelia – which is a JAK inhibitor for treating pruritus and atopic dermatitis in dogs launched in late September 2024 – is expected to fuel revenue growth and further strengthen Elanco Animal Health Incorporated (NYSE:ELAN)’s market position over the next few years.

Page 4 of 12